Loading…
Gefitinib induces EGFR and α5β1 integrin co-endocytosis in glioblastoma cells
Overexpression of EGFR drives glioblastomas (GBM) cell invasion but these tumours remain resistant to EGFR-targeted therapies such as tyrosine kinase inhibitors (TKIs). Endocytosis, an important modulator of EGFR function, is often dysregulated in glioma cells and is associated with therapy resistan...
Saved in:
Published in: | Cellular and molecular life sciences : CMLS 2021-03, Vol.78 (6), p.2949-2962 |
---|---|
Main Authors: | , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c509t-2f0c172a5052709127b08578258588e96a045db8d78bfb472657afee3a82f8a93 |
---|---|
cites | cdi_FETCH-LOGICAL-c509t-2f0c172a5052709127b08578258588e96a045db8d78bfb472657afee3a82f8a93 |
container_end_page | 2962 |
container_issue | 6 |
container_start_page | 2949 |
container_title | Cellular and molecular life sciences : CMLS |
container_volume | 78 |
creator | Blandin, Anne-Florence Cruz Da Silva, Elisabete Mercier, Marie-Cécile Glushonkov, Oleksandr Didier, Pascal Dedieu, Stéphane Schneider, Cristophe Devy, Jessica Etienne-Selloum, Nelly Dontenwill, Monique Choulier, Laurence Lehmann, Maxime |
description | Overexpression of EGFR drives glioblastomas (GBM) cell invasion but these tumours remain resistant to EGFR-targeted therapies such as tyrosine kinase inhibitors (TKIs). Endocytosis, an important modulator of EGFR function, is often dysregulated in glioma cells and is associated with therapy resistance. However, the impact of TKIs on EGFR endocytosis has never been examined in GBM cells. In the present study, we showed that gefitinib and other tyrosine kinase inhibitors induced EGFR accumulation in early-endosomes as a result of an increased endocytosis. Moreover, TKIs trigger early-endosome re-localization of another membrane receptor, the fibronectin receptor alpha5beta1 integrin, a promising therapeutic target in GBM that regulates physiological EGFR endocytosis and recycling in cancer cells. Super-resolution dSTORM imaging showed a close-proximity between beta1 integrin and EGFR in intracellular membrane compartments of gefitinib-treated cells, suggesting their potential interaction. Interestingly, integrin depletion delayed gefitinib-mediated EGFR endocytosis. Co-endocytosis of EGFR and alpha5beta1 integrin may alter glioma cell response to gefitinib. Using an in vitro model of glioma cell dissemination from spheroid, we showed that alpha5 integrin-depleted cells were more sensitive to TKIs than alpha5-expressing cells. This work provides evidence for the first time that EGFR TKIs can trigger massive EGFR and alpha5beta1 integrin co-endocytosis, which may modulate glioma cell invasiveness under therapeutic treatment. |
doi_str_mv | 10.1007/s00018-020-03686-6 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11073190</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2505799425</sourcerecordid><originalsourceid>FETCH-LOGICAL-c509t-2f0c172a5052709127b08578258588e96a045db8d78bfb472657afee3a82f8a93</originalsourceid><addsrcrecordid>eNp9kcFu1DAQhi0EoqXwAhxQJC5wCIzt2B6fUFW1W6SVKiGQuFlO4mxdZe1iJ5X6WPAgfSa8ZCnQAyfbM9_8M-OfkJcU3lEA9T4DAMUaGNTAJcpaPiKHtClPDYo-3t8lsq8H5FnOV4UWyORTcsA5FZQjHpKLlRv85INvKx_6uXO5Ol2dfaps6Ku77-LuBy3xyW2SD1UXaxf62N1OMftc4tVm9LEdbZ7i1ladG8f8nDwZ7Jjdi_15RL6cnX4-Oa_XF6uPJ8fruhOgp5oN0FHFrADBFGjKVAsoFDKBAtFpaaERfYu9wnZoG8WkUHZwjltkA1rNj8iHRfd6breu71yYkh3NdfJbm25NtN78mwn-0mzijaEUFKcaisLbReHyQd358drsYsA5QoPyhhb2zb5bit9mlyez9Xm3rw0uztmwRiitqBSioK8foFdxTqH8hWFlW6V1w3YUW6guxZyTG-4noGB25prFXFPMNb_MNbIUvfp75_uS324WgC9ALqmwcelP7__I_gR2IK7W</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2505799425</pqid></control><display><type>article</type><title>Gefitinib induces EGFR and α5β1 integrin co-endocytosis in glioblastoma cells</title><source>PubMed Central(OA)</source><source>Springer Link</source><creator>Blandin, Anne-Florence ; Cruz Da Silva, Elisabete ; Mercier, Marie-Cécile ; Glushonkov, Oleksandr ; Didier, Pascal ; Dedieu, Stéphane ; Schneider, Cristophe ; Devy, Jessica ; Etienne-Selloum, Nelly ; Dontenwill, Monique ; Choulier, Laurence ; Lehmann, Maxime</creator><creatorcontrib>Blandin, Anne-Florence ; Cruz Da Silva, Elisabete ; Mercier, Marie-Cécile ; Glushonkov, Oleksandr ; Didier, Pascal ; Dedieu, Stéphane ; Schneider, Cristophe ; Devy, Jessica ; Etienne-Selloum, Nelly ; Dontenwill, Monique ; Choulier, Laurence ; Lehmann, Maxime</creatorcontrib><description>Overexpression of EGFR drives glioblastomas (GBM) cell invasion but these tumours remain resistant to EGFR-targeted therapies such as tyrosine kinase inhibitors (TKIs). Endocytosis, an important modulator of EGFR function, is often dysregulated in glioma cells and is associated with therapy resistance. However, the impact of TKIs on EGFR endocytosis has never been examined in GBM cells. In the present study, we showed that gefitinib and other tyrosine kinase inhibitors induced EGFR accumulation in early-endosomes as a result of an increased endocytosis. Moreover, TKIs trigger early-endosome re-localization of another membrane receptor, the fibronectin receptor alpha5beta1 integrin, a promising therapeutic target in GBM that regulates physiological EGFR endocytosis and recycling in cancer cells. Super-resolution dSTORM imaging showed a close-proximity between beta1 integrin and EGFR in intracellular membrane compartments of gefitinib-treated cells, suggesting their potential interaction. Interestingly, integrin depletion delayed gefitinib-mediated EGFR endocytosis. Co-endocytosis of EGFR and alpha5beta1 integrin may alter glioma cell response to gefitinib. Using an in vitro model of glioma cell dissemination from spheroid, we showed that alpha5 integrin-depleted cells were more sensitive to TKIs than alpha5-expressing cells. This work provides evidence for the first time that EGFR TKIs can trigger massive EGFR and alpha5beta1 integrin co-endocytosis, which may modulate glioma cell invasiveness under therapeutic treatment.</description><identifier>ISSN: 1420-682X</identifier><identifier>EISSN: 1420-9071</identifier><identifier>DOI: 10.1007/s00018-020-03686-6</identifier><identifier>PMID: 33151388</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Biochemistry ; Biomedical and Life Sciences ; Biomedicine ; Brain cancer ; Brain Neoplasms - metabolism ; Brain Neoplasms - pathology ; Cell Biology ; Cell culture ; Cell growth ; Cell Line, Tumor ; Cell Membrane - drug effects ; Cell Membrane - metabolism ; Cell Movement - drug effects ; Depletion ; Endocytosis ; Endocytosis - drug effects ; Endosomes ; Endosomes - metabolism ; Epidermal Growth Factor - metabolism ; Epidermal growth factor receptors ; ErbB Receptors - metabolism ; Fibronectin ; Gefitinib ; Gefitinib - pharmacology ; Glioblastoma ; Glioblastoma - metabolism ; Glioblastoma - pathology ; Glioblastoma cells ; Glioma cells ; Growth factors ; Humans ; Image resolution ; Impact resistance ; Integrin alpha5beta1 - antagonists & inhibitors ; Integrin alpha5beta1 - genetics ; Integrin alpha5beta1 - metabolism ; Invasiveness ; Kinases ; Life Sciences ; Localization ; Medical prognosis ; Membranes ; Original ; Original Article ; Protein Kinase Inhibitors - pharmacology ; Protein turnover ; Protein-tyrosine kinase ; Proteins ; Reagents ; Receptors ; Regulation ; RNA Interference ; RNA, Small Interfering - metabolism ; Targeted cancer therapy ; Tumors ; Tyrosine</subject><ispartof>Cellular and molecular life sciences : CMLS, 2021-03, Vol.78 (6), p.2949-2962</ispartof><rights>Springer Nature Switzerland AG 2020</rights><rights>Springer Nature Switzerland AG 2020.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c509t-2f0c172a5052709127b08578258588e96a045db8d78bfb472657afee3a82f8a93</citedby><cites>FETCH-LOGICAL-c509t-2f0c172a5052709127b08578258588e96a045db8d78bfb472657afee3a82f8a93</cites><orcidid>0000-0003-2447-7738 ; 0000-0002-5235-3014 ; 0000-0003-1493-9775 ; 0000-0003-3417-5661 ; 0000-0002-4558-4594</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11073190/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11073190/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33151388$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-03380486$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Blandin, Anne-Florence</creatorcontrib><creatorcontrib>Cruz Da Silva, Elisabete</creatorcontrib><creatorcontrib>Mercier, Marie-Cécile</creatorcontrib><creatorcontrib>Glushonkov, Oleksandr</creatorcontrib><creatorcontrib>Didier, Pascal</creatorcontrib><creatorcontrib>Dedieu, Stéphane</creatorcontrib><creatorcontrib>Schneider, Cristophe</creatorcontrib><creatorcontrib>Devy, Jessica</creatorcontrib><creatorcontrib>Etienne-Selloum, Nelly</creatorcontrib><creatorcontrib>Dontenwill, Monique</creatorcontrib><creatorcontrib>Choulier, Laurence</creatorcontrib><creatorcontrib>Lehmann, Maxime</creatorcontrib><title>Gefitinib induces EGFR and α5β1 integrin co-endocytosis in glioblastoma cells</title><title>Cellular and molecular life sciences : CMLS</title><addtitle>Cell. Mol. Life Sci</addtitle><addtitle>Cell Mol Life Sci</addtitle><description>Overexpression of EGFR drives glioblastomas (GBM) cell invasion but these tumours remain resistant to EGFR-targeted therapies such as tyrosine kinase inhibitors (TKIs). Endocytosis, an important modulator of EGFR function, is often dysregulated in glioma cells and is associated with therapy resistance. However, the impact of TKIs on EGFR endocytosis has never been examined in GBM cells. In the present study, we showed that gefitinib and other tyrosine kinase inhibitors induced EGFR accumulation in early-endosomes as a result of an increased endocytosis. Moreover, TKIs trigger early-endosome re-localization of another membrane receptor, the fibronectin receptor alpha5beta1 integrin, a promising therapeutic target in GBM that regulates physiological EGFR endocytosis and recycling in cancer cells. Super-resolution dSTORM imaging showed a close-proximity between beta1 integrin and EGFR in intracellular membrane compartments of gefitinib-treated cells, suggesting their potential interaction. Interestingly, integrin depletion delayed gefitinib-mediated EGFR endocytosis. Co-endocytosis of EGFR and alpha5beta1 integrin may alter glioma cell response to gefitinib. Using an in vitro model of glioma cell dissemination from spheroid, we showed that alpha5 integrin-depleted cells were more sensitive to TKIs than alpha5-expressing cells. This work provides evidence for the first time that EGFR TKIs can trigger massive EGFR and alpha5beta1 integrin co-endocytosis, which may modulate glioma cell invasiveness under therapeutic treatment.</description><subject>Biochemistry</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Brain cancer</subject><subject>Brain Neoplasms - metabolism</subject><subject>Brain Neoplasms - pathology</subject><subject>Cell Biology</subject><subject>Cell culture</subject><subject>Cell growth</subject><subject>Cell Line, Tumor</subject><subject>Cell Membrane - drug effects</subject><subject>Cell Membrane - metabolism</subject><subject>Cell Movement - drug effects</subject><subject>Depletion</subject><subject>Endocytosis</subject><subject>Endocytosis - drug effects</subject><subject>Endosomes</subject><subject>Endosomes - metabolism</subject><subject>Epidermal Growth Factor - metabolism</subject><subject>Epidermal growth factor receptors</subject><subject>ErbB Receptors - metabolism</subject><subject>Fibronectin</subject><subject>Gefitinib</subject><subject>Gefitinib - pharmacology</subject><subject>Glioblastoma</subject><subject>Glioblastoma - metabolism</subject><subject>Glioblastoma - pathology</subject><subject>Glioblastoma cells</subject><subject>Glioma cells</subject><subject>Growth factors</subject><subject>Humans</subject><subject>Image resolution</subject><subject>Impact resistance</subject><subject>Integrin alpha5beta1 - antagonists & inhibitors</subject><subject>Integrin alpha5beta1 - genetics</subject><subject>Integrin alpha5beta1 - metabolism</subject><subject>Invasiveness</subject><subject>Kinases</subject><subject>Life Sciences</subject><subject>Localization</subject><subject>Medical prognosis</subject><subject>Membranes</subject><subject>Original</subject><subject>Original Article</subject><subject>Protein Kinase Inhibitors - pharmacology</subject><subject>Protein turnover</subject><subject>Protein-tyrosine kinase</subject><subject>Proteins</subject><subject>Reagents</subject><subject>Receptors</subject><subject>Regulation</subject><subject>RNA Interference</subject><subject>RNA, Small Interfering - metabolism</subject><subject>Targeted cancer therapy</subject><subject>Tumors</subject><subject>Tyrosine</subject><issn>1420-682X</issn><issn>1420-9071</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kcFu1DAQhi0EoqXwAhxQJC5wCIzt2B6fUFW1W6SVKiGQuFlO4mxdZe1iJ5X6WPAgfSa8ZCnQAyfbM9_8M-OfkJcU3lEA9T4DAMUaGNTAJcpaPiKHtClPDYo-3t8lsq8H5FnOV4UWyORTcsA5FZQjHpKLlRv85INvKx_6uXO5Ol2dfaps6Ku77-LuBy3xyW2SD1UXaxf62N1OMftc4tVm9LEdbZ7i1ladG8f8nDwZ7Jjdi_15RL6cnX4-Oa_XF6uPJ8fruhOgp5oN0FHFrADBFGjKVAsoFDKBAtFpaaERfYu9wnZoG8WkUHZwjltkA1rNj8iHRfd6breu71yYkh3NdfJbm25NtN78mwn-0mzijaEUFKcaisLbReHyQd358drsYsA5QoPyhhb2zb5bit9mlyez9Xm3rw0uztmwRiitqBSioK8foFdxTqH8hWFlW6V1w3YUW6guxZyTG-4noGB25prFXFPMNb_MNbIUvfp75_uS324WgC9ALqmwcelP7__I_gR2IK7W</recordid><startdate>20210301</startdate><enddate>20210301</enddate><creator>Blandin, Anne-Florence</creator><creator>Cruz Da Silva, Elisabete</creator><creator>Mercier, Marie-Cécile</creator><creator>Glushonkov, Oleksandr</creator><creator>Didier, Pascal</creator><creator>Dedieu, Stéphane</creator><creator>Schneider, Cristophe</creator><creator>Devy, Jessica</creator><creator>Etienne-Selloum, Nelly</creator><creator>Dontenwill, Monique</creator><creator>Choulier, Laurence</creator><creator>Lehmann, Maxime</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><general>Springer Verlag</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7QP</scope><scope>7QR</scope><scope>7SS</scope><scope>7T5</scope><scope>7T7</scope><scope>7TK</scope><scope>7TM</scope><scope>7TO</scope><scope>7U7</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>P64</scope><scope>PATMY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PYCSY</scope><scope>Q9U</scope><scope>RC3</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-2447-7738</orcidid><orcidid>https://orcid.org/0000-0002-5235-3014</orcidid><orcidid>https://orcid.org/0000-0003-1493-9775</orcidid><orcidid>https://orcid.org/0000-0003-3417-5661</orcidid><orcidid>https://orcid.org/0000-0002-4558-4594</orcidid></search><sort><creationdate>20210301</creationdate><title>Gefitinib induces EGFR and α5β1 integrin co-endocytosis in glioblastoma cells</title><author>Blandin, Anne-Florence ; Cruz Da Silva, Elisabete ; Mercier, Marie-Cécile ; Glushonkov, Oleksandr ; Didier, Pascal ; Dedieu, Stéphane ; Schneider, Cristophe ; Devy, Jessica ; Etienne-Selloum, Nelly ; Dontenwill, Monique ; Choulier, Laurence ; Lehmann, Maxime</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c509t-2f0c172a5052709127b08578258588e96a045db8d78bfb472657afee3a82f8a93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Biochemistry</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Brain cancer</topic><topic>Brain Neoplasms - metabolism</topic><topic>Brain Neoplasms - pathology</topic><topic>Cell Biology</topic><topic>Cell culture</topic><topic>Cell growth</topic><topic>Cell Line, Tumor</topic><topic>Cell Membrane - drug effects</topic><topic>Cell Membrane - metabolism</topic><topic>Cell Movement - drug effects</topic><topic>Depletion</topic><topic>Endocytosis</topic><topic>Endocytosis - drug effects</topic><topic>Endosomes</topic><topic>Endosomes - metabolism</topic><topic>Epidermal Growth Factor - metabolism</topic><topic>Epidermal growth factor receptors</topic><topic>ErbB Receptors - metabolism</topic><topic>Fibronectin</topic><topic>Gefitinib</topic><topic>Gefitinib - pharmacology</topic><topic>Glioblastoma</topic><topic>Glioblastoma - metabolism</topic><topic>Glioblastoma - pathology</topic><topic>Glioblastoma cells</topic><topic>Glioma cells</topic><topic>Growth factors</topic><topic>Humans</topic><topic>Image resolution</topic><topic>Impact resistance</topic><topic>Integrin alpha5beta1 - antagonists & inhibitors</topic><topic>Integrin alpha5beta1 - genetics</topic><topic>Integrin alpha5beta1 - metabolism</topic><topic>Invasiveness</topic><topic>Kinases</topic><topic>Life Sciences</topic><topic>Localization</topic><topic>Medical prognosis</topic><topic>Membranes</topic><topic>Original</topic><topic>Original Article</topic><topic>Protein Kinase Inhibitors - pharmacology</topic><topic>Protein turnover</topic><topic>Protein-tyrosine kinase</topic><topic>Proteins</topic><topic>Reagents</topic><topic>Receptors</topic><topic>Regulation</topic><topic>RNA Interference</topic><topic>RNA, Small Interfering - metabolism</topic><topic>Targeted cancer therapy</topic><topic>Tumors</topic><topic>Tyrosine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Blandin, Anne-Florence</creatorcontrib><creatorcontrib>Cruz Da Silva, Elisabete</creatorcontrib><creatorcontrib>Mercier, Marie-Cécile</creatorcontrib><creatorcontrib>Glushonkov, Oleksandr</creatorcontrib><creatorcontrib>Didier, Pascal</creatorcontrib><creatorcontrib>Dedieu, Stéphane</creatorcontrib><creatorcontrib>Schneider, Cristophe</creatorcontrib><creatorcontrib>Devy, Jessica</creatorcontrib><creatorcontrib>Etienne-Selloum, Nelly</creatorcontrib><creatorcontrib>Dontenwill, Monique</creatorcontrib><creatorcontrib>Choulier, Laurence</creatorcontrib><creatorcontrib>Lehmann, Maxime</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>ProQuest_Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Agriculture Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest_Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>ProQuest Biological Science Journals</collection><collection>Research Library (Corporate)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Environmental Science Collection</collection><collection>ProQuest Central Basic</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cellular and molecular life sciences : CMLS</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Blandin, Anne-Florence</au><au>Cruz Da Silva, Elisabete</au><au>Mercier, Marie-Cécile</au><au>Glushonkov, Oleksandr</au><au>Didier, Pascal</au><au>Dedieu, Stéphane</au><au>Schneider, Cristophe</au><au>Devy, Jessica</au><au>Etienne-Selloum, Nelly</au><au>Dontenwill, Monique</au><au>Choulier, Laurence</au><au>Lehmann, Maxime</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Gefitinib induces EGFR and α5β1 integrin co-endocytosis in glioblastoma cells</atitle><jtitle>Cellular and molecular life sciences : CMLS</jtitle><stitle>Cell. Mol. Life Sci</stitle><addtitle>Cell Mol Life Sci</addtitle><date>2021-03-01</date><risdate>2021</risdate><volume>78</volume><issue>6</issue><spage>2949</spage><epage>2962</epage><pages>2949-2962</pages><issn>1420-682X</issn><eissn>1420-9071</eissn><abstract>Overexpression of EGFR drives glioblastomas (GBM) cell invasion but these tumours remain resistant to EGFR-targeted therapies such as tyrosine kinase inhibitors (TKIs). Endocytosis, an important modulator of EGFR function, is often dysregulated in glioma cells and is associated with therapy resistance. However, the impact of TKIs on EGFR endocytosis has never been examined in GBM cells. In the present study, we showed that gefitinib and other tyrosine kinase inhibitors induced EGFR accumulation in early-endosomes as a result of an increased endocytosis. Moreover, TKIs trigger early-endosome re-localization of another membrane receptor, the fibronectin receptor alpha5beta1 integrin, a promising therapeutic target in GBM that regulates physiological EGFR endocytosis and recycling in cancer cells. Super-resolution dSTORM imaging showed a close-proximity between beta1 integrin and EGFR in intracellular membrane compartments of gefitinib-treated cells, suggesting their potential interaction. Interestingly, integrin depletion delayed gefitinib-mediated EGFR endocytosis. Co-endocytosis of EGFR and alpha5beta1 integrin may alter glioma cell response to gefitinib. Using an in vitro model of glioma cell dissemination from spheroid, we showed that alpha5 integrin-depleted cells were more sensitive to TKIs than alpha5-expressing cells. This work provides evidence for the first time that EGFR TKIs can trigger massive EGFR and alpha5beta1 integrin co-endocytosis, which may modulate glioma cell invasiveness under therapeutic treatment.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>33151388</pmid><doi>10.1007/s00018-020-03686-6</doi><tpages>14</tpages><orcidid>https://orcid.org/0000-0003-2447-7738</orcidid><orcidid>https://orcid.org/0000-0002-5235-3014</orcidid><orcidid>https://orcid.org/0000-0003-1493-9775</orcidid><orcidid>https://orcid.org/0000-0003-3417-5661</orcidid><orcidid>https://orcid.org/0000-0002-4558-4594</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1420-682X |
ispartof | Cellular and molecular life sciences : CMLS, 2021-03, Vol.78 (6), p.2949-2962 |
issn | 1420-682X 1420-9071 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11073190 |
source | PubMed Central(OA); Springer Link |
subjects | Biochemistry Biomedical and Life Sciences Biomedicine Brain cancer Brain Neoplasms - metabolism Brain Neoplasms - pathology Cell Biology Cell culture Cell growth Cell Line, Tumor Cell Membrane - drug effects Cell Membrane - metabolism Cell Movement - drug effects Depletion Endocytosis Endocytosis - drug effects Endosomes Endosomes - metabolism Epidermal Growth Factor - metabolism Epidermal growth factor receptors ErbB Receptors - metabolism Fibronectin Gefitinib Gefitinib - pharmacology Glioblastoma Glioblastoma - metabolism Glioblastoma - pathology Glioblastoma cells Glioma cells Growth factors Humans Image resolution Impact resistance Integrin alpha5beta1 - antagonists & inhibitors Integrin alpha5beta1 - genetics Integrin alpha5beta1 - metabolism Invasiveness Kinases Life Sciences Localization Medical prognosis Membranes Original Original Article Protein Kinase Inhibitors - pharmacology Protein turnover Protein-tyrosine kinase Proteins Reagents Receptors Regulation RNA Interference RNA, Small Interfering - metabolism Targeted cancer therapy Tumors Tyrosine |
title | Gefitinib induces EGFR and α5β1 integrin co-endocytosis in glioblastoma cells |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T07%3A03%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Gefitinib%20induces%20EGFR%20and%20%CE%B15%CE%B21%20integrin%20co-endocytosis%20in%20glioblastoma%20cells&rft.jtitle=Cellular%20and%20molecular%20life%20sciences%20:%20CMLS&rft.au=Blandin,%20Anne-Florence&rft.date=2021-03-01&rft.volume=78&rft.issue=6&rft.spage=2949&rft.epage=2962&rft.pages=2949-2962&rft.issn=1420-682X&rft.eissn=1420-9071&rft_id=info:doi/10.1007/s00018-020-03686-6&rft_dat=%3Cproquest_pubme%3E2505799425%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c509t-2f0c172a5052709127b08578258588e96a045db8d78bfb472657afee3a82f8a93%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2505799425&rft_id=info:pmid/33151388&rfr_iscdi=true |